2918 related articles for article (PubMed ID: 28975890)
21. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections.
Bismar TA; Bianco FJ; Zhang H; Li X; Sarkar FH; Sakr WA; Grignon DJ; Che M
Pathology; 2003 Dec; 35(6):513-7. PubMed ID: 14660102
[TBL] [Abstract][Full Text] [Related]
22. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
[TBL] [Abstract][Full Text] [Related]
23. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
24. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
26. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma.
Ebru T; Fulya OP; Hakan A; Vuslat YC; Necdet S; Nuray C; Filiz O
Int Braz J Urol; 2017; 43(3):440-454. PubMed ID: 27583351
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
[TBL] [Abstract][Full Text] [Related]
30. hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.
Lastraioli E; Pillozzi S; Mari A; Tellini R; Duranti C; Baldazzi V; Venturini S; Minervini A; Lapini A; Nesi G; Carini M; Arcangeli A
Eur J Surg Oncol; 2020 Jan; 46(1):209-215. PubMed ID: 31679954
[TBL] [Abstract][Full Text] [Related]
31. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma.
Huang Y; Murakami T; Sano F; Kondo K; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Eur Urol; 2009 Oct; 56(4):690-8. PubMed ID: 18930582
[TBL] [Abstract][Full Text] [Related]
32. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
36. Tissue-based molecular markers for renal cell carcinoma.
Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
[TBL] [Abstract][Full Text] [Related]
37. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
Serrano-Oviedo L; Giménez-Bachs JM; Nam-Cha SY; Cimas FJ; García-Cano J; Sánchez-Prieto R; Salinas-Sánchez AS
Urol Oncol; 2017 Mar; 35(3):114.e15-114.e22. PubMed ID: 27836247
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
39. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
40. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
